Cellectar Biosciences, Inc.
CLRB
$4.88
-$0.05-1.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.70M | 25.64M | 23.92M | 18.46M | 14.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.18M | 51.78M | 51.58M | 47.67M | 42.26M |
| Operating Income | -46.18M | -51.78M | -51.58M | -47.67M | -42.26M |
| Income Before Tax | -24.48M | -44.52M | -50.17M | -53.02M | -62.28M |
| Income Tax Expenses | 66.00K | 66.00K | -60.00K | -60.00K | -60.00K |
| Earnings from Continuing Operations | -24.54 | -44.58 | -50.11 | -52.96 | -62.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.54M | -44.58M | -50.11M | -52.96M | -62.22M |
| EBIT | -46.18M | -51.78M | -51.58M | -47.67M | -42.26M |
| EBITDA | -45.92M | -51.49M | -51.29M | -47.40M | -42.02M |
| EPS Basic | -17.94 | -40.87 | -54.89 | -90.19 | -116.53 |
| Normalized Basic EPS | -11.18 | -25.52 | -34.38 | -56.44 | -72.91 |
| EPS Diluted | -23.54 | -46.48 | -60.60 | -94.96 | -116.65 |
| Normalized Diluted EPS | -11.08 | -25.42 | -34.28 | -56.42 | -72.91 |
| Average Basic Shares Outstanding | 5.44M | 4.88M | 3.99M | 3.05M | 2.23M |
| Average Diluted Shares Outstanding | 5.51M | 4.95M | 4.05M | 3.11M | 2.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |